IMJUDO
PeakmAbBLAINTRAVENOUSINJECTABLE
Approved
Nov 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
IMJUDO by AstraZeneca is ctla-4 is a negative regulator of t-cell activity. Approved for anaplastic lymphoma kinase (alk) genomic tumor aberrations. First approved in 2022.
Drug data last refreshed 13h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMJUDO (tremelimumab-actl) is a monoclonal antibody that blocks CTLA-4, a negative regulator of T-cell immunity, to treat patients with ALK-positive anaplastic lymphoma kinase genomic tumor aberrations. By releasing CTLA-4-mediated inhibition, it enhances T-cell proliferation and anti-tumor activity. This immunotherapy represents a checkpoint inhibitor approach in oncology.
$0.002BPart D
PeakEarly commercial phase with moderate Part D uptake (65 claims in 2023) suggests ongoing market penetration efforts and growing team investment in medical affairs and field infrastructure.
Mechanism of Action
CTLA-4 is a negative regulator of T-cell activity. Tremelimumab-actl is a monoclonal antibody that binds to CTLA-4 and blocks the interaction with its ligands CD80 and CD86, releasing CTLA-4-mediated inhibition of T-cell activation. In synergistic mouse tumor models, blocking CTLA-4 activity…
Indications (1)
Clinical Trials (3)
Imjudo & Imfinzi PMS
Started Apr 2025
246 enrolled
Hepatocellular Carcinoma
Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
Started Jun 2023
296 enrolled
Carcinoma, Non-Small-Cell Lung
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Started May 2023
1,200 enrolled
Unresectable Hepatocellular Carcinoma
Worked on IMJUDO at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.